Drugs · acquisition-cost intelligence
LABETALOL HCl
· ingredient labetalolAlpha and beta blocking agents· LABETALOL HYDROCHLORIDE 100 mg/20mL; LABETALOL HYDROCHLORIDE 200 mg/40mL; LABETALOL HYDROCHLORIDE 5 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.23540
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 4 weeks.
2025-05-212026-05-20
Same-ingredient options by acquisition cost
Other labetalol products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Labetalol HCL | $0.14527 | −$0.09010 |
| Labetalol HCL | $0.20455 | −$0.03080 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.